Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter re

  • PDF / 1,159,686 Bytes
  • 9 Pages / 595.276 x 790.866 pts Page_size
  • 23 Downloads / 133 Views

DOWNLOAD

REPORT


RESEARCH ARTICLE

Open Access

Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study Hiroaki Nomoto1, Naoki Morimoto1, Kouichi Miura1*, Shunji Watanabe1, Yoshinari Takaoka1, Hiroshi Maeda1, Takahiro Sasaki2, Yohei Koyashiki2, Hidekazu Kurata3, Norikatsu Numao4, Norio Isoda1 and Hironori Yamamoto1

Abstract  Background:  Chronic liver disease (CLD) is often complicated by severe thrombocytopenia (platelet count  50,000/µL at baseline: the proportions of patients who did not require platelet transfusion were 84–96%, which might be overestimated. Methods:  The efficacy and safety of lusutrombopag were retrospectively investigated in CLD patients with platelet count of  50,000/µL. However, lusutrombopag is effective and safe for CLD patients with a platelet count of